Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort
<h3 dir="ltr">Background</h3><p dir="ltr">Alzheimer's disease (AD) is a leading cause of dementia with societal and economic burdens. While recent therapies offer disease-modifying potential, concerns remain about efficacy and safety. Glucagon-like peptide-...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513524074545152 |
|---|---|
| author | Majd A AbuAlrob (23073877) |
| author2 | Adham Itbaisha (22392508) Yahya Kayed Abujwaid (23073880) Ayah Abulehia (23073883) Abdallah Hussein (21696423) Boulenouar Mesraoua (16936932) |
| author2_role | author author author author author |
| author_facet | Majd A AbuAlrob (23073877) Adham Itbaisha (22392508) Yahya Kayed Abujwaid (23073880) Ayah Abulehia (23073883) Abdallah Hussein (21696423) Boulenouar Mesraoua (16936932) |
| author_role | author |
| dc.creator.none.fl_str_mv | Majd A AbuAlrob (23073877) Adham Itbaisha (22392508) Yahya Kayed Abujwaid (23073880) Ayah Abulehia (23073883) Abdallah Hussein (21696423) Boulenouar Mesraoua (16936932) |
| dc.date.none.fl_str_mv | 2025-10-16T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1177/25424823251388650 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Exploring_the_neuroprotective_role_of_GLP-1_agonists_against_Alzheimer_s_disease_Real-world_evidence_from_a_propensity-matched_cohort/31169407 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences Alzheimer's disease diabetes glucagon-like peptide-1 receptor agonists |
| dc.title.none.fl_str_mv | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3 dir="ltr">Background</h3><p dir="ltr">Alzheimer's disease (AD) is a leading cause of dementia with societal and economic burdens. While recent therapies offer disease-modifying potential, concerns remain about efficacy and safety. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in type 2 diabetes, show neuroprotective effects via reduced neuroinflammation and amyloid burden.</p><h3 dir="ltr">Objective</h3><p dir="ltr">To evaluate whether GLP-1RA use is associated with a reduced risk of incident dementia in adults aged ≥50 years using real-world data.</p><h3 dir="ltr">Methods</h3><p dir="ltr">We conducted a retrospective cohort study using the TriNetX platform, analyzing records from 142 healthcare organizations. Adults aged ≥50 were included, comparing GLP-1RA users (liraglutide, semaglutide, dulaglutide, exenatide, albiglutide) to non-users. Propensity-score matching balanced demographics and comorbidities. Incident dementia, defined by ICD-10 codes, was analyzed with Cox proportional-hazards models.</p><h3 dir="ltr">Results</h3><p dir="ltr">Matched cohorts (n = 147,505 each) had similar baseline characteristics. Dementia incidence was lower in GLP-1RA users (0.20% versus 0.44%), with a hazard ratio of 0.30 (95% CI 0.28–0.33; p < 0.001).</p><h3 dir="ltr">Conclusions</h3><p dir="ltr">GLP-1RA use was associated with a 70% reduced dementia risk, warranting further clinical evaluation.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Journal of Alzheimer's Disease Reports<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1177/25424823251388650" target="_blank">https://dx.doi.org/10.1177/25424823251388650</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_3cec0f3b9d667c445a9650877f6d9431 |
| identifier_str_mv | 10.1177/25424823251388650 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/31169407 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohortMajd A AbuAlrob (23073877)Adham Itbaisha (22392508)Yahya Kayed Abujwaid (23073880)Ayah Abulehia (23073883)Abdallah Hussein (21696423)Boulenouar Mesraoua (16936932)Biomedical and clinical sciencesMedical biochemistry and metabolomicsNeurosciencesPharmacology and pharmaceutical sciencesAlzheimer's diseasediabetesglucagon-like peptide-1 receptor agonists<h3 dir="ltr">Background</h3><p dir="ltr">Alzheimer's disease (AD) is a leading cause of dementia with societal and economic burdens. While recent therapies offer disease-modifying potential, concerns remain about efficacy and safety. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in type 2 diabetes, show neuroprotective effects via reduced neuroinflammation and amyloid burden.</p><h3 dir="ltr">Objective</h3><p dir="ltr">To evaluate whether GLP-1RA use is associated with a reduced risk of incident dementia in adults aged ≥50 years using real-world data.</p><h3 dir="ltr">Methods</h3><p dir="ltr">We conducted a retrospective cohort study using the TriNetX platform, analyzing records from 142 healthcare organizations. Adults aged ≥50 were included, comparing GLP-1RA users (liraglutide, semaglutide, dulaglutide, exenatide, albiglutide) to non-users. Propensity-score matching balanced demographics and comorbidities. Incident dementia, defined by ICD-10 codes, was analyzed with Cox proportional-hazards models.</p><h3 dir="ltr">Results</h3><p dir="ltr">Matched cohorts (n = 147,505 each) had similar baseline characteristics. Dementia incidence was lower in GLP-1RA users (0.20% versus 0.44%), with a hazard ratio of 0.30 (95% CI 0.28–0.33; p < 0.001).</p><h3 dir="ltr">Conclusions</h3><p dir="ltr">GLP-1RA use was associated with a 70% reduced dementia risk, warranting further clinical evaluation.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Journal of Alzheimer's Disease Reports<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1177/25424823251388650" target="_blank">https://dx.doi.org/10.1177/25424823251388650</a></p>2025-10-16T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1177/25424823251388650https://figshare.com/articles/journal_contribution/Exploring_the_neuroprotective_role_of_GLP-1_agonists_against_Alzheimer_s_disease_Real-world_evidence_from_a_propensity-matched_cohort/31169407CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/311694072025-10-16T09:00:00Z |
| spellingShingle | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort Majd A AbuAlrob (23073877) Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences Alzheimer's disease diabetes glucagon-like peptide-1 receptor agonists |
| status_str | publishedVersion |
| title | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort |
| title_full | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort |
| title_fullStr | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort |
| title_full_unstemmed | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort |
| title_short | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort |
| title_sort | Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort |
| topic | Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences Alzheimer's disease diabetes glucagon-like peptide-1 receptor agonists |